FDA Gives Stamp of Approval for Clinical Psilocybin Trials

““It’s great that the FDA is finally recognizing that the substances our government has criminalized and stigmatized for decades have therapeutic value,” said Ifetayo Harvey, a Marketing Coordinator for the Drug Policy Alliance. “However, I’m afraid that the route of medicalization and FDA recognition will only lead to corporatization of mushrooms and preclude accessibility for everyone.”

“What I also see coming from this trial,” she continued, “is a more synthesized version of psilocybin detached from its cultural significance connected to thepractices of the Native American people of Mexico and Central America. I think it’s important that we acknowledge this medicine is attached to people’s cultural practices.”